Glass House Brands (GLAS) Non-Current Debt (2020 - 2026)
Glass House Brands' (GLAS) quarterly Non-Current Debt came in at $67.8 million in Q1 2026, up 3.07% year-on-year from $65.8 million in Q1 2025, and down 1.18% on a QoQ basis from $68.6 million in Q4 2025.
Glass House Brands (GLAS) Non-Current Debt (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Non-Current Debt data on file, last reported at $67.8 million in Q1 2026.
- On a quarterly basis, Non-Current Debt rose 3.07% year-over-year to $67.8 million in Q1 2026; TTM through Mar 2026 was $67.8 million, a 3.07% increase from a year earlier, with the FY2025 full-year figure at $68.6 million, up 35.76% from the prior year.
- Non-Current Debt for Q1 2026 stood at $67.8 million, down from $68.6 million in the prior quarter.
- Over the last five years, Non-Current Debt for GLAS reached as high as $68.8 million in Q3 2025 and fell as low as $45.1 million in Q1 2022.
- Historically, Non-Current Debt has averaged $60.4 million across 5 years, with a median of $62.6 million in 2022.
- Across the five-year window, Non-Current Debt surged 30048.31% in 2022 and dropped 18.27% in 2024, its largest moves.
- Year by year, Non-Current Debt stood at $62.6 million in 2022, then decreased by 9.75% to $56.5 million in 2023, then declined by 10.55% to $50.6 million in 2024, then jumped by 35.76% to $68.6 million in 2025, then slipped by 1.18% to $67.8 million in 2026.
- Per Business Quant data, the three most recent Non-Current Debt figures were $67.8 million in Q1 2026, $68.6 million in Q4 2025, and $68.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 67.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.82 Mn |
| Dec 31, 2025 | 68.63 Mn |
| Sep 30, 2025 | 68.81 Mn |
| Jun 30, 2025 | 65.85 Mn |
| Mar 31, 2025 | 65.80 Mn |
| Dec 31, 2024 | 50.55 Mn |
| Sep 30, 2024 | 52.20 Mn |
| Jun 30, 2024 | 53.70 Mn |
| Mar 31, 2024 | 54.88 Mn |
| Dec 31, 2023 | 56.51 Mn |
| Sep 30, 2023 | 63.87 Mn |
| Jun 30, 2023 | 63.63 Mn |
| Mar 31, 2023 | 62.89 Mn |
| Dec 31, 2022 | 62.62 Mn |
| Sep 30, 2022 | 62.41 Mn |
| Jun 30, 2022 | 61.89 Mn |
| Mar 31, 2022 | 45.07 Mn |
| Dec 31, 2021 | 44.82 Mn |
| Sep 30, 2021 | 207,000.00 |
| Jun 30, 2021 | 217,000.00 |